Rani Therapeutics Holdings, Inc.

RANI Healthcare Biotechnology

Rani Therapeutics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.6 million, up 58.9% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 77.8% and free cash flow fell 55.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.64 0.04 −5.88%
Market cap
$94.8M
P/E
0.0×
Fwd P/E
−4.3×
Dividend yield
—
F-score
n/a
Altman Z
−1.33
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(155.24%) (195.02%) (131.87%) 913.68%

+8 more TTM periods

ROA
(77.54%) (77.47%) (62.30%) (105.50%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(64.95%) (87.01%) (71.69%) 213.42%
Average Days of Receivables
147.62 223.09 207.38 —
Free Cash Flow per Share
(0.11) (0.10) (0.28) (0.60)
Free Cash Flow
(20.34) (17.11) (18.80) (27.78)
Other line items

Show all line items

Columns are period end dates